Synonyms 36 kDa nucleolar protein HNP36, Delayed-early response protein 12, DER12 + [10] |
Introduction Bidirectional uniporter involved in the facilitative transport of nucleosides and nucleobases, and contributes to maintaining their cellular homeostasis (PubMed:9396714, PubMed:9478986, PubMed:12527552, PubMed:10722669, PubMed:12590919, PubMed:21795683, PubMed:16214850). Functions as a Na(+)-independent, passive transporter (PubMed:9478986). Involved in the transport of nucleosides such as inosine, adenosine, uridine, thymidine, cytidine and guanosine (PubMed:9396714, PubMed:9478986, PubMed:12527552, PubMed:10722669, PubMed:12590919, PubMed:21795683, PubMed:16214850). Also able to transport purine nucleobases (hypoxanthine, adenine, guanine) and pyrimidine nucleobases (thymine, uracil) (PubMed:21795683, PubMed:16214850). Involved in nucleoside transport at basolateral membrane of kidney cells, allowing liver absorption of nucleoside metabolites (PubMed:12527552). Mediates apical nucleoside uptake into Sertoli cells, thereby regulating the transport of nucleosides in testis across the blood-testis-barrier (PubMed:23639800). Mediates both the influx and efflux of hypoxanthine in skeletal muscle microvascular endothelial cells to control the amount of intracellular hypoxanthine available for xanthine oxidase-mediated ROS production (By similarity).
Non functional nucleoside transporter protein for adenosine or thymidine tranport. Does not express on cell membrane. |
Target |
Mechanism ENT2 inhibitors [+1] |
Active Org. Gennao BioStartup [+1] |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date20 Jan 1800 |
Target |
Mechanism ENT2 inhibitors [+1] |
Active Org. Gennao BioStartup |
Originator Org. Gennao BioStartup |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date20 Jan 1800 |
Target |
Mechanism ENT2 inhibitors |
Active Org.- |
Originator Org. |
Active Indication- |
Inactive Indication- |
Drug Highest Phase- |
First Approval Ctry. / Loc.- |
First Approval Date20 Jan 1800 |